| Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. P McLaughlin, AJ Grillo-López, BK Link, R Levy, MS Czuczman, ... Journal of clinical oncology 16 (8), 2825-2833, 1998 | 3655 | 1998 |
| Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood W Wagner, F Wein, A Seckinger, M Frankhauser, U Wirkner, U Krause, ... Experimental hematology 33 (11), 1402-1416, 2005 | 1740 | 2005 |
| Replicative senescence of mesenchymal stem cells: a continuous and organized process W Wagner, P Horn, M Castoldi, A Diehlmann, S Bork, R Saffrich, V Benes, ... PloS one 3 (5), e2213, 2008 | 1312 | 2008 |
| Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) M Pfreundschuh, J Schubert, M Ziepert, R Schmits, M Mohren, ... The lancet oncology 9 (2), 105-116, 2008 | 1299 | 2008 |
| Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma A Engert, A Plütschow, HT Eich, A Lohri, B Dörken, P Borchmann, ... New England Journal of Medicine 363 (7), 640-652, 2010 | 1107 | 2010 |
| Human haematopoietic stem cell lineage commitment is a continuous process L Velten, SF Haas, S Raffel, S Blaszkiewicz, S Islam, BP Hennig, C Hirche, ... Nature cell biology 19 (4), 271-281, 2017 | 955 | 2017 |
| Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial A Engert, H Haverkamp, C Kobe, J Markova, C Renner, A Ho, J Zijlstra, ... The Lancet 379 (9828), 1791-1799, 2012 | 759 | 2012 |
| Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma … N Schmitz, L Trümper, M Ziepert, M Nickelsen, AD Ho, B Metzner, N Peter, ... Blood, The Journal of the American Society of Hematology 116 (18), 3418-3425, 2010 | 695 | 2010 |
| Aging and replicative senescence have related effects on human stem and progenitor cells W Wagner, S Bork, P Horn, D Krunic, T Walenda, A Diehlmann, V Benes, ... PloS one 4 (6), e5846, 2009 | 553 | 2009 |
| Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group … HT Eich, V Diehl, H Görgen, T Pabst, J Markova, J Debus, A Ho, B Dörken, ... Journal of Clinical Oncology 28 (27), 4199-4206, 2010 | 520 | 2010 |
| VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma BM Beckermann, G Kallifatidis, A Groth, D Frommhold, A Apel, J Mattern, ... British journal of cancer 99 (4), 622-631, 2008 | 503 | 2008 |
| DNA methylation pattern changes upon long‐term culture and aging of human mesenchymal stromal cells S Bork, S Pfister, H Witt, P Horn, B Korn, AD Ho, W Wagner Aging cell 9 (1), 54-63, 2010 | 495 | 2010 |
| A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis G Palladini, U Hegenbart, P Milani, C Kimmich, A Foli, AD Ho, MV Rosin, ... Blood, The Journal of the American Society of Hematology 124 (15), 2325-2332, 2014 | 475 | 2014 |
| Rituximab therapy of patients with B-cell chronic lymphocytic leukemia D Huhn, C von Schilling, M Wilhelm, AD Ho, M Hallek, R Kuse, W Knauf, ... Blood, The Journal of the American Society of Hematology 98 (5), 1326-1331, 2001 | 471 | 2001 |
| Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p K Neben, HM Lokhorst, A Jauch, U Bertsch, T Hielscher, B van der Holt, ... Blood, The Journal of the American Society of Hematology 119 (4), 940-948, 2012 | 465 | 2012 |
| Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma J Hillengass, K Fechtner, MA Weber, T Bäuerle, S Ayyaz, C Heiss, ... Journal of Clinical Oncology 28 (9), 1606-1610, 2010 | 456 | 2010 |
| Suppression of T-cell functions by human granulocyte arginase M Munder, H Schneider, C Luckner, T Giese, CD Langhans, JM Fuentes, ... Blood 108 (5), 1627-1634, 2006 | 444 | 2006 |
| Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity M Munder, F Mollinedo, J Calafat, J Canchado, C Gil-Lamaignere, ... Blood 105 (6), 2549-2556, 2005 | 402 | 2005 |
| Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study H Wandt, K Schaefer-Eckart, K Wendelin, B Pilz, M Wilhelm, ... The Lancet 380 (9850), 1309-1316, 2012 | 368 | 2012 |
| Mesenchymal stem cell preparations—comparing apples and oranges W Wagner, AD Ho Stem cell reviews 3, 239-248, 2007 | 358 | 2007 |
Wolfgang WagnerRWTH Aachen Medical SchoolVerified email at ukaachen.de
